Skip to main content

Table 5 Characteristics and medical costs of patients in the persistent group

From: Persistence rates and medical costs of biological therapies for psoriasis treatment in Japan: a real-world data study using a claims database

 

Total

BT-naïve

ADL

IFX

UST

Sub

total

ADL

IFX

UST

Sub

total

Number of patients

6

6

29

42

4

6

23

33

Average Age

50.8

44.7

45.0

46.0

54.0

44.7

44.8

45.9

%Female

16.7%

16.7%

17.2%

16.7%

25.0%

16.7%

21.7%

21.2%

Cost (pre)

¥1092

¥1062

¥925

¥988

¥360

¥1062

¥597

¥653

In 1000

JPY unit

IP

¥55

¥603

¥315

¥340

¥0

¥603

¥201

¥250

OP

¥876

¥398

¥418

¥473

¥263

¥398

¥211

¥251

RX

¥161

¥61

¥192

¥175

¥97

¥61

¥186

¥152

Cost increase

¥1606

¥2246

¥1875

¥1883

¥2433

¥2246

¥2211

¥2244

In 1000

JPY unit

IP

- ¥55

- ¥174

- ¥147

- ¥140

¥0

- ¥174

- ¥98

- ¥100

OP

¥1365

¥2446

¥2114

¥2054

¥2461

¥2446

¥2380

¥2402

RX

¥295

- ¥26

- ¥91

- ¥30

- ¥27

- ¥26

- ¥71

- ¥57

  1. ADL Adalimumab, IFX Infliximab, UST Ustekinumab, pre:12 months pre-initiation, cost increase: increase from pre to post 12 months post-initiation, JPY Japanese Yen, IP inpatient medical costs, OP outpatient medical cost, RX costs of drugs other than BTs